

CLAIMS:

1. A method of preparing a highly phosphorylated  $\alpha$ -glucosidase comprising:  
contacting said  $\alpha$ -glucosidase with an isolated GlcNAc-phosphotransferase to  
5 produce a modified  $\alpha$ -glucosidase; and  
contacting said modified  $\alpha$ -glucosidase with an isolated phosphodiester  $\alpha$ -  
GlcNAcase.

2. The method of Claim 1, further comprising purifying said phosphorylated  $\alpha$ -  
10 glucosidase after said contacting with the isolated phosphodiester  $\alpha$ -GlcNAcase.

3. The method of Claim 1, further comprising purifying said modified  $\alpha$ -glucosidase  
prior to said contacting with the isolated phosphodiester  $\alpha$ -GlcNAcase.

4. A highly phosphorylated  $\alpha$ -glucosidase obtained by the method of Claim 1.

5. A pharmaceutical composition comprising the highly phosphorylated  $\alpha$ -  
15 glucosidase of Claim 4 and a pharmaceutically acceptable carrier.

6. A method of treating a patient suffering from Pompe's disease, comprising  
administering to a patient in need thereof the pharmaceutical composition of Claim 5 in an  
amount sufficient to treat said disease.

7. The method of Claim 1, wherein said GlcNAc-phosphotransferase comprises SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

8. The method of Claim 1, wherein said GlcNAc-phosphotransferase comprises amino acid 1-928 of SEQ ID NO:1, amino acids 1-328 of SEQ ID NO:2, and amino acids 25-305 of SEQ ID NO:3.

9. The method of Claim 1, wherein said GlcNAc-phosphotransferase comprises SEQ ID NO:15, SEQ ID NO:8, and SEQ ID NO:9.

10. The method of Claim 1, wherein said phosphodiester  $\alpha$ -GlcNAcase comprises the amino acid SEQ ID NO:6.

11. The method of Claim 1, wherein said phosphodiester  $\alpha$ -GlcNAcase comprises amino acids 50-515 of SEQ ID NO:6.

12. A method of producing a highly phosphorylated  $\alpha$ -glucosidase comprising:  
culturing transformed cells comprising a recombinant polynucleotide which encodes for a recombinant  $\alpha$ -glucosidase in the presence of at least one  $\alpha$  1,2-mannosidase inhibitor;  
recovering a high mannose recombinant  $\alpha$ -glucosidase from said transformed cell;  
contacting said high mannose recombinant  $\alpha$ -glucosidase with an isolated GlcNAc phosphotransferase to produce a modified  $\alpha$ -glucosidase; and  
contacting said modified  $\alpha$ -glucosidase with an isolated phosphodiester  $\alpha$ -GlcNAcase.

13. The method of Claim 12, wherein said at least one  $\alpha$  1,2-mannosidase inhibitor is selected from the group consisting of deoxymannojirimycin, kifunensine, D-Mannonolactam amidrazone, and N-butyl-deoxymannojirimycin.

14. The method of Claim 13, wherein the  $\alpha$  1,2-mannosidase inhibitor is kifunensine.

15. The method of Claim 13, wherein the  $\alpha$  1,2 mannosidase inhibitor is deoxymannojirimycin.

16. The method of Claim 12, wherein the at least one 1,2 mannosidase inhibitor is deoxymannojirimycin and kifunensine.

17. A highly phosphorylated  $\alpha$ -glucosidase prepared according to the method of Claim 12.

18. A pharmaceutical composition comprising the highly phosphorylated  $\alpha$ -glucosidase of Claim 17 and a pharmaceutically acceptable carrier.

19. A method of treating a patient suffering from Pompe's disease, comprising administering to a patient in need thereof the pharmaceutical composition of Claim 18 in an amount sufficient to treat said disease.

20. The method of Claim 12, wherein said GlcNAc-phosphotransferase comprises SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

21. The method of Claim 12, wherein said GlcNAc-phosphotransferase comprises amino acid 1-928 of SEQ ID NO:1, amino acids 1-328 of SEQ ID NO:2, and amino acids 25-305 of SEQ ID NO:3.

22. The method of Claim 12, wherein said GlcNAc-phosphotransferase comprises  
5 SEQ ID NO:15, SEQ ID NO:8, and SEQ ID NO:9.

23. The method of Claim 12, wherein said phosphodiester  $\alpha$ -GlcNAcase comprises the amino acid SEQ ID NO:6.

24. The method of Claim 12, wherein said phosphodiester  $\alpha$ -GlcNAcase comprises amino acids 50-515 of SEQ ID NO:6.

H:\novazyme\210119US0CONT-pa.wpd